Should You Buy Femasys Inc (FEMY) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
0.550
1 Day change
-6.64%
52 Week Range
1.800
Analysis Updated At
2026/01/28
Not a good buy right now for a Beginner long-term investor with $50k–$100k who is impatient. FEMY is in a clear bearish trend (SMA200 > SMA20 > SMA5) and is trading right on key support (~0.584). With continued losses and no fresh catalysts in the last week, the risk/reward is unfavorable at this moment despite a bullish analyst initiation.
Technical Analysis
Price/Trend: Bearish structure with moving averages stacked bearishly (SMA_200 > SMA_20 > SMA_5), implying the primary trend is down.
Momentum: MACD histogram is slightly positive (0.00314) but contracting—suggests any bounce is weakening rather than strengthening.
RSI: RSI_6 = 34.41 (near oversold but still labeled neutral here); this can support short bounces, but not a confirmed reversal.
Levels: Current price ~0.5869 is sitting on S1 = 0.584. A clean break below raises downside risk toward S2 = 0.548. Upside rebound targets would be Pivot 0.644, then R1 0.703.
Pattern-based short-term bias: Similar-pattern stats suggest ~-0.59% next day, +1.96% next week, +3.44% next month—modestly positive beyond 1 day, but not strong enough to override the broader downtrend.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Positive Catalysts
Analyst initiation: Laidlaw initiated Buy with a $6.50 price target (high upside vs. sub-$1 price), citing women’s health product opportunities (FemaSeed channel expansion; FemBloc heading to pivotal study).
Revenue growth: 2025/Q3 revenue increased 31.44% YoY to $729,394, showing some commercial progress.
Potential clinical milestones: FemBloc moving toward a pivotal clinical study could become an event-driven catalyst when timelines/updates arrive.
Neutral/Negative Catalysts
Profitability deterioration: 2025/Q3 net loss widened to -$4.19M (down -22.45% YoY), EPS down to -0.10 (-58.33% YoY), and gross margin fell to 47.97% (-7.50% YoY).
Financial Performance
Latest quarter: 2025/Q3. Growth is mixed: revenue rose 31.44% YoY to $729,394, but profitability worsened—net income fell to -$4,194,821 (loss widened by ~22.45% YoY), EPS declined to -0.10 (-58.33% YoY), and gross margin decreased to 47.97% (-7.50% YoY). Overall, topline momentum exists, but the business is still burning cash and margins are slipping—unfavorable for a beginner long-term buyer seeking a straightforward hold.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent analyst activity: Only one noted update—on 2025-11-20, Laidlaw (Yale Jen) initiated coverage with a Buy rating and a $6.50 price target.
Wall Street pro view (pros): Large stated upside from a low base; product pipeline narrative (FemaSeed market opportunity, FemBloc pivotal study) could re-rate shares if execution is strong.
Cons: This is still development-stage with widening losses and weakening margins; without near-term catalysts or a confirmed technical reversal, the stock can remain pressured even with a bullish price target.
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 4.75 USD with a low forecast of 3 USD and a high forecast of 6.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 4.75 USD with a low forecast of 3 USD and a high forecast of 6.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.587
Low
3
Averages
4.75
High
6.5
Current: 0.587
Low
3
Averages
4.75
High
6.5
Laidlaw
Yale Jen
initiated
$6.50
AI Analysis
2025-11-20
Reason
Laidlaw
Yale Jen
Price Target
$6.50
AI Analysis
2025-11-20
initiated
Reason
Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.
JonesResearch
Buy
downgrade
$10 -> $6
2025-05-13
Reason
JonesResearch
Price Target
$10 -> $6
2025-05-13
downgrade
Buy
Reason
JonesResearch lowered the firm's price target on Femasys to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FEMY
